Andrae Lavon Vandross
YOU?
Author Swipe
View article: 541 ctDNA as a potential surrogate biomarker for response to combination vilastobart and atezolizumab in heavily pretreated microsatellite stable (MSS) metastatic colorectal cancer (mCRC) (NCT04896697)
541 ctDNA as a potential surrogate biomarker for response to combination vilastobart and atezolizumab in heavily pretreated microsatellite stable (MSS) metastatic colorectal cancer (mCRC) (NCT04896697) Open
View article: 575 First-in-human phase 1, open-label, dose-finding study of ZM008 as monotherapy and in combination with anti PD1 antibody in patients with advanced solid tumors
575 First-in-human phase 1, open-label, dose-finding study of ZM008 as monotherapy and in combination with anti PD1 antibody in patients with advanced solid tumors Open
View article: Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors
Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors Open
Background This was a first-in-human, phase I, dose-escalation study evaluating the safety, pharmacokinetics, and preliminary efficacy of zavondemstat (TACH101), an epigenetic targeting inhibitor of KDM4 histone demethylase, in patients wi…
View article: 1455 Phase 1 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors
1455 Phase 1 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors Open
View article: 1464 Phase 1 results of OR502, an antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in patients with advanced cancers
1464 Phase 1 results of OR502, an antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in patients with advanced cancers Open
View article: 680 Adaptive design elements in a Ph 1–2 study of OR502, a novel antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in response to evolving Ph 1 data and changing regulatory environment
680 Adaptive design elements in a Ph 1–2 study of OR502, a novel antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in response to evolving Ph 1 data and changing regulatory environment Open
View article: 986 Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual agent approach targeting immunosuppressive polyamine metabolism
986 Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual agent approach targeting immunosuppressive polyamine metabolism Open
View article: 133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors Open
XTX101 is a tumor-activated, Fc-enhanced, high affinity anti-CTLA-4 monoclonal antibody designed with masking peptides that block the CTLA-4 antigen-binding regions. The masking peptides, covalently linked, are cleaved by proteases upregul…
View article: Case Reports in the Age of Twitter
Case Reports in the Age of Twitter Open